In the acute phase after TAC, the LIPUS therapy up-regulated the protein levels of VEGF, eNOS, and CD31, and enhanced the phosphorylation of Akt, but not that of ERK1/2 (Figs 5 and S5). Here, MAPK3 is linked to persistent truncus arteriosus.